Revenue
2022
2023
2024
2025
Mereo BioPharma Group plc (MREO)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $500,000 | $0 | $10.0M | $0 |
| Research & development | $17.8M | $20.9M | $17.4M | $29.5M |
| Operating expenses | $700,000 | $700,000 | $700,000 | $900,000 |
| Operating income | −$40.1M | −$47.4M | −$28.4M | −$54.4M |
| EBITDAderived | −$39.5M | −$46.8M | −$27.9M | −$54.2M |
| Net income | −$41.9M | −$43.3M | −$29.5M | −$42.2M |
| Basic EPSper diluted share | -$0.05 | -$0.06 | -$0.04 | -$0.07 |
| Diluted EPSper diluted share | -$0.05 | -$0.06 | -$0.04 | -$0.07 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 13, 2024Form 4 | Scots-Knight DeniseChief Executive Officer | SellAmerican Depositary Shares representing Ordinary Shares | 60.0K | $4.22 | $253.4K | 808.9K |
| Sep 13, 2024Form 4 | Lewicki John A.Chief Scientific Officer | SellAmerican Depositary Shares representing Ordinary Shares | 10.9K | $4.22 | $46.2K | 78.6K |
| Sep 13, 2024Form 4 | Sermon CharlesGeneral Counsel | SellAmerican Depositary Shares representing Ordinary Shares | 20.9K | $4.22 | $88.4K | 219.1K |
| Sep 13, 2024Form 4 | Fox Christine AnnChief Financial Officer | SellAmerican Depositary Shares representing Ordinary Shares | 19.2K | $4.22 | $80.8K | 89.3K |
| Sep 13, 2024Form 4 | Hughes-Wilson AlexandraSee Remarks | SellAmerican Depositary Shares representing Ordinary Shares | 84.0K | $4.22 | $354.5K | 50.5K |